Editas Medicine Presents Five Abstracts at the 28th Annual Meeting of the American Society of Gene and Cell Therapy

Editas Medicine, a pioneering gene editing company, is making significant progress towards the clinic with its in vivo medicines in preclinical development for people living with serious diseases. At the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), the company will present five abstracts, including one oral presentation, highlighting its preclinical data in support of its development of transformative in vivo gene editing medicines. These presentations demonstrate the company's ability to increase the level of a protein to address diseases caused by loss of function or deleterious mutations via its differentiated gene upregulation editing strategy. The company's progress with targeted lipid nanoparticles (tLNPs) showcases the potential to execute its gene upregulation strategy across multiple tissues with its 'plug 'n play' approach.

Key Takeaways:

• Editas Medicine is presenting five abstracts at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), including one oral presentation, highlighting its preclinical data in support of its development of transformative in vivo gene editing medicines.
• The company is presenting proof of concept for an undisclosed liver target using in vivo CRISPR editing to upregulate target protein expression and reduce a disease-associated biomarker in a relevant mouse disease model.
• Editas Medicine's progress with targeted lipid nanoparticles (tLNPs) showcases the potential to execute its gene upregulation strategy across multiple tissues with its 'plug 'n play' approach.
• The company is presenting four poster presentations, including design and development of improved LNP targeting ligands for in vivo hematopoietic stem cell editing, chemically modified AsCas12a guide RNAs for increased potency of LNP-delivered gene editing cargos, and in vivo gene editing and disease-associated biomarker reduction for multiple liver targets in non-human primates.
• Editas Medicine's presentations are scheduled to take place from May 13-17, 2025, in New Orleans, LA, and virtually.

Statistics:

• Five abstracts have been accepted for presentation at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), including one oral presentation.
• Four poster presentations are scheduled to take place during the conference.
• The presentations highlight the company's preclinical data in support of its development of transformative in vivo gene editing medicines.
• The company's progress with tLNPs showcases the potential to execute its gene upregulation strategy across multiple tissues with its 'plug 'n play' approach.
• Editas Medicine is the exclusive licensee of Broad Institute's Cas12a patent estate and Broad Institute and Harvard University's Cas9 patent estates for human medicines.

Sources:

• GlobeNewswire, "Editas Medicine Announces Five Abstracts Accepted for Presentation at the 28th Annual Meeting of the American Society of Gene and Cell Therapy"
• Editas Medicine, "About Editas Medicine"
• American Society of Gene and Cell Therapy, "28th Annual Meeting"